Aminoglutethimide Therapy for Advanced Carcinoma of the Prostate

Publisher Website
Google Scholar
Abstract
The results of aminoglutethimide treatment of 12 patients with advanced progressive metastatic carcinoma of the prostate are reported. As judged by performance status and analgesic requirements, there were subjective improvements in 75% of the group; side effects were minimal. No consistent objective improvements were observed, but decrease in plasma androstenedione and testotsterone was associated with subjective improvement in most responders. Mean survival of patients following introduction of aminoglutethimide was 6.5 mo. Aminoglutethimide medical adrenalectomy appears safe and effective in the management of advanced carcinoma of the prostate.